Drug intelligence / Profile preview

VCE-006.3

Development stage: Preclinical
Lead developer: Emerald Health Biotechnology España
Modality: Small Molecules
Administration: Oral

Overview

VCE-006.3 is a preclinical-stage small molecule developed by Emerald Health Biotechnology España (VivaCell Biotechnology Spain). It functions as an antagonist of the G protein-coupled receptor 55 (GPR55), a non-classical cannabinoid receptor involved in the regulation of energy homeostasis and lipid metabolism. The compound is specifically targeted toward the treatment of androgenic obesity, aiming to address visceral fat accumulation and associated metabolic dysregulation. As of 2023, the program remains in preclinical development.

Other names: VCE-006.3VCE006.3VCE 006.3

Targets

GPR55 (G protein-coupled receptor 55)

Beyond the preview

Go deeper on VCE-006.3.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VCE-006.3.

Explore the full profile